The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
C Patel, JML Brotherton, A Pillsbury… - …, 2018 - eurosurveillance.org
Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
Interventions to improve HPV vaccine uptake: a systematic review
EB Walling, N Benzoni, J Dornfeld, R Bhandari… - …, 2016 - publications.aap.org
OBJECTIVE: Identification of effective strategies is necessary to optimize uptake of the HPV
vaccine. We systematically reviewed the literature for national and international …
vaccine. We systematically reviewed the literature for national and international …
Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
SN Tabrizi, JML Brotherton, JM Kaldor… - The Lancet infectious …, 2014 - thelancet.com
Background After the introduction of a quadrivalent human papillomavirus (HPV) vaccination
programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and …
programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and …
The uptake of human papillomavirus vaccination and its associated factors among adolescents: a systematic review
AY Loke, ML Kwan, YT Wong… - Journal of primary care …, 2017 - journals.sagepub.com
Background: The purpose of this review was to explore the uptake of the human
papillomavirus (HPV) vaccination, its associated factors, and the facilitators of and barriers to …
papillomavirus (HPV) vaccination, its associated factors, and the facilitators of and barriers to …
Very low prevalence of vaccine human papillomavirus types among 18-to 35-year old Australian women 9 years following implementation of vaccination
DA Machalek, SM Garland… - The Journal of …, 2018 - academic.oup.com
Introduction A quadrivalent human papillomavirus vaccination program targeting females
aged 12–13 years commenced in Australia in 2007, with catch-up vaccination of 14–26 year …
aged 12–13 years commenced in Australia in 2007, with catch-up vaccination of 14–26 year …
A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program
D Novakovic, ATL Cheng, Y Zurynski… - The Journal of …, 2018 - academic.oup.com
Background Recurrent respiratory papillomatosis is a rare but morbid disease caused by
human papillomavirus (HPV) types 6 and 11. Infection is preventable through HPV …
human papillomavirus (HPV) types 6 and 11. Infection is preventable through HPV …
Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment …
Summary Background Australia's National Cervical Screening Program currently
recommends cytological screening every 2 years for women aged 18–69 years. Human …
recommends cytological screening every 2 years for women aged 18–69 years. Human …
[HTML][HTML] Is one dose of human papillomavirus vaccine as effective as three?: a national cohort analysis
JML Brotherton, A Budd, C Rompotis, N Bartlett… - Papillomavirus …, 2019 - Elsevier
Aim Prophylactic human papillomavirus (HPV) vaccines are highly effective at preventing
pre–cancerous cervical lesions when given in a three–dose schedule. Some post–hoc trial …
pre–cancerous cervical lesions when given in a three–dose schedule. Some post–hoc trial …
Human papillomavirus vaccination coverage, policies, and practical implementation across Europe
NH Nguyen-Huu, N Thilly, T Derrough, E Sdona… - Vaccine, 2020 - Elsevier
Background Our objectives were to describe Human Papillomavirus vaccination coverage
rates (HPV-VCR), policies, and practical steps for programme implementation that may be …
rates (HPV-VCR), policies, and practical steps for programme implementation that may be …
[HTML][HTML] An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015
M Vichnin, P Bonanni, NP Klein… - The Pediatric …, 2015 - journals.lww.com
Background: A quadrivalent human papillomavirus (HPV4) type 6/11/16/18 vaccine
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …
(GARDASIL/SILGARD®) has been licensed in many countries around the world for the …